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Cancer is a leading cause of death worldwide. It ac-
counted for 12 . 7 million new cases and 7 . 6 million 
deaths in 20081）. While human life expectancy is in-
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?????????：The reports of multiple primary malignant neoplasm （MPMN） have increased due to the de-
velopment of imaging technologies that have influenced the extension of the 5-year relative survival rate 
for all cancers. Integrated positron emission and computed tomography （PET/CT） with 18F-fluorodeoxyglu-
cose （FDG） has shown its advantages for detecting, staging, evaluating the prognosis, and offering better 
insights for survivors, their families and physicians. The aim of this study was to retrospectively investigate 
the impact of whole-body FDG-PET/CT in detecting MPMN during the initial staging work-up of gastroin-
testinal and breast malignancy, and to describe their characteristics.
???????：The cases were identified by reviewing the Dokkyo Medical University Hospital PET Center’s 
database, searching for patients referred from the Department of Surgical Oncology and the Department of 
Gastroenterological Surgery, who underwent preoperative staging with whole-body FDG PET/CT at our 
center between January 2007 and December 2009. A total of 778 patients matched these criteria. Of them, 
40 PET/CT reports mentioned suspicious cases of MPMN. The medical records of these 40 cases were re-
trieved and examined. The follow-up data of these patients was reviewed until February 2010.
???????：Of 778, 32 patients were diagnosed with additional unexpected cancers, which 27 （3.5％） were 
incidental double cancers and 5 （0.64％） had triple primary lesions. Overall 37 MPMN, twelve corresponded 
to stage 0, nineteen to stages I−II, three to stages III−IV, and three remained uncertain. Sensitivity and 
positive predictive value of FDG PET/CT in detecting a controversial lesion were 76.5％ and 70.3％, respec-
tively. The colorectum was the most common site for synchronous MPMN （17 of 37 cancers；45.9％）, fol-
lowed by stomach （9；24.3％）, prostate （3；8.1％）, thyroid （3；8.1％）, breast （2；5.4％）, biliary duct （1；
2.7％）, kidney （1；2.7％）, and lung （1；2.7％）.
???????????：FDG PET/CT was useful for finding multiple primary malignant neoplasm with a relatively 
high sensitivity. Physicians should pay special attention to rule out the presence of unexpected additional 
primary lesions in initial staging work-up for colorectal cancer.
???? ????： PET/CT, FDG, multiple primary malignant neoplasm, synchronous cancer
????????
Gustavo Kishimoto
for a histopathological proven primary malignant neo-
plasm （index lesion）, incidentally had another cancer. 
Multiple primary malignant neoplasm diagnosis and 
their histological and topographic classification were 
done according to the International Rules for Multiple 
Primary Cancers8）. Although no consensus was pres-
ent on synchronous and metachronous tumor defini-
tion, in the current study were defined as follows：
synchronous cancers were second primary malignant 
neoplasm occurring within 6 months of the diagnosis 
of the first primary cancer, whereas metachronous 
cancer were defined as those that were diagnosed af-
ter an interval of ＞ 6 months.
The cases were identified by reviewing the DMUH-
PET Center’s database, searching for patients referred 
from the Department of Surgical Oncology and the De-
partment of Gastroenterological Surgery, who under-
went preoperative staging of gastrointestinal and 
breast malignancy with whole-body FDG PET/CT at 
our center between January 2007 and December 2009. 
A total of 778 patients matched these criteria. Of them, 
40 PET/CT reports mentioned suspicious cases of 
MPMN. The medical records of these 40 cases were 
retrieved and examined. The follow-up data of these 
patients was reviewed until February 2010.
Data collection
Data was collected between October 2009 and Feb-
ruary 2010 from the DMUH-PET Center’s electronic 
database and the patients’ clinical records from the 
hospital electronic database. Using a record sheet de-
signed for the objectives of this study, we collected de-
mographic characteristics （age, sex）, risk factors for 
cancer, such as body mass index （BMI）, tobacco smok-
ing, alcohol drinking, history of cancer in first-degree 
family members and presence of diabetes mellitus, ar-
terial hypertension and/or personal oncological history.
Data collected on the index primary malignant neo-
plasm and additional synchronous cancers included：
site and size, PET/CT TNM staging, histopathology 
and pathological staging, treatment, occurrence of re-
lapse and/or metastases and standardized uptake val-
ue （SUV）. SUV is defined as the retention of FDG nor-
malized to an injected dose and patient body weight. It 
is an established index for quantifying glucose meta-
bolic activity in tissues. For this study, an increased 
creasing in recent years, cancer incidence may be ex-
pected to increase to 27 million new cases by the year 
20302） It is also reasonable to assume that synchro-
nous cancers, multiple primary malignant neoplasm 
（MPMN） occurring simultaneously, may no longer be 
a rare medical incidental curiosity, but may become a 
great threat；one worthy of study not only because of 
its own significance but also because it offers many di-
rections of approach to the overall study of neoplasm. 
In 2009, the American Cancer Society highlighted the 
increased number of new cases of MPMN due to the 
development of screening tests that has influenced the 
extension of the 5-year relative survival rate for all 
cancers combined from 50％ in 1975-1977 to 66％ in 
1996-20043）. In this scenario, ageing societies, such as 
Japan4）, should be aware of this increasing menace.
Integrated positron emission and computed tomog-
raphy （PET/CT） with 18F-fluorodeoxyglucose （FDG） 
is a novel clinical imaging modality that has shown 
throughout the last decade its advantages for detect-
ing, staging, evaluating the prognosis of various tu-
mors, and offering better insights for survivors and 
their families and physicians5〜7）.
The objective of this study was to retrospectively 
investigate the impact of whole-body FDG-PET/CT 
in detecting MPMN during the initial staging work-up 
of gastrointestinal and breast malignancy, and to de-
scribe their characteristics.
???????
Study design and site
This was a descriptive-retrospective study conduct-
ed at the Dokkyo Medical University Hospital PET 
Center （DMUH-PET Center）, a quaternary referral 
care center affiliated to the tertiary referral care 1,167-
bed university hospital of Dokkyo Medical University 
in Mibu, Tochigi, Japan. The DMUH-PET Center was 
established in 2005 , as the first PET/CT provider in 
the northern Kanto region, which embraces the Gun-
ma, Ibaraki and Tochigi prefectures. The DMUH-PET 
Center annually performs a mean of 3 ,600 examina-
tions, mainly for oncological purpose.
Participants
The cases were cancer patients, who, during the 
preoperative staging with whole-body FDG PET/CT 
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predictive value （PPV） of 70.3％ . Of 778, 32 patients 
（4 .1％） were diagnosed with additional unexpected 
cancers, which 27 （3.5％） were incidental double can-
cers and 5 （0.6％） had triple primary lesions；giving a 
total of 37 synchronous malignant lesions.
Table 1 shows the demographic characteristics and 
some of the known risk factors for cancer of the 32 in-
vestigated cases （male＝19；female＝13）. The mean 
age of the cases was 71 .1±10.5 years；and the age 
range between 71 and 80 years was the most preva-
lent （56.3％；13 males and 5 females）.
History of cancer in first-degree family members 
was observed in nine of the patients （28 .1％）, from 
which 55 . 6％ had 2 or more relatives with cancer. 
Risky habits were mainly present in males, 34 .4％ of 
whom were smokers, 18.8％ drinkers, and 15.6％ both 
smokers and drinkers. Excluding 6 patients without 
addictive behavior records, 25 .0％ consumed alcohol, 
with a mean of 19 .9±17.1 g of ethanol per week. Of 
the six patients （18.8％） with BMI ≥  25 , four were 
uptake with a maximum SUV （SUVmax） greater than 
3.0 was considered as a suspicious lesion for neoplasm 
that required further examination9）.
Statistical analysis
Data analysis was performed using SPSS for Win-
dows version 16 . Descriptive analysis was performed 
for the studied variables. Frequencies were deter-
mined for all categorical variables, while mean and 
standard deviation was calculated for continuous vari-
ables. Sensitivity and positive predictive value of PET/
CT to detect MPMN was calculated.
???????
From the 40 PET/CT that were reported as suspi-
cious of MPMN, eight were not confirmed as MPMN 
with the pathologic study：six benign tumors （located 
in the thyroid, colon, breast, pancreas, lung）, a liver 
metastasis, and one without pathological diagnosis. 
These resulted in a sensitivity of 76.5％ and a positive 
??（1） （2011） 11
???????　Demographic characteristics and risk factors of 32 patients with MPMN
Age（years） 71.1±10.5
Sex（M/F） 19/13
History of cancer in first-degree family members  9（28.1％）
　One relative with cancer  4（12.5％）
　Two or more relatives w/cancer  5（15.6％）
Habitual smoking 15（46.9％）
　Male 11（34.4％）
　Female  4（12.5％）
　Pack Year＊ 30.6±22.6
Habitual alcohol intake  8（25.0％）
　Male  6（18.8％）
　Female  2（ 6.3％）
　Gram of ethanol/week 19.9±17.1
Diabetes Mellitus  7（21.9％）
Body mass index 21.8±3.5
　Underweight  6（18.8％）
　Normal 20（62.5％）
　Overweight  4（12.5％）
　Obesity  2（6.3％）
Arterial Hypertension 14（43.8％）
Patients’ Previous Oncological History  1（3.1％）†
Abbreviations：MPMN, multiple primary malignant neoplasm
＊ Pack Year＝number of packs times years reported. 1 pack＝20 cigarettes
† Patient had a previous breast cancer ten years before the present study.
Gustavo Kishimoto12 DJMS
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MPMN：impact of PET/CT
PET/CT （Table 3-2）18〜26）. In Western countries’ stud-
ies, a literature review reported a prevalence of 
MPMN between 0.73％ and 11.7％27）.
Although patients in our study showed an age range 
between 41 and 85 years, majority of them （69％） 
were older than 70 years. Previous studies have also 
described a higher prevalence of MPMN among this 
age bracket 28 ,29）, and it is a criterion that should be 
taken into consideration for performing PET/CT dur-
ing the initial staging and/or follow-up planning.
Alcohol drinking and tobacco smoking have been 
previously described as risk factors for MPMN3,11,30,31）. 
In our study, although there were no statistically pre-
dominant risk factors, there was a tendency to tobacco 
smoking （46 .9％）, history of cancer in first-degree 
family member （28.1％） and alcohol drinking （25.0％） 
in patients with MPMN. A recent study of the impact 
of tobacco smoking on the subsequent risk of cancer in 
Japan, showed an overall frequency of smoking of 53.9
％ （men 83％ , women 8 .9％） in patients who devel-
oped cancer32）. This dramatically contrasts with our 
results, which show a lower frequency for men （57.9
％） and a much higher frequency for women （30.8％）. 
These results may suggest a stronger relation be-
tween tobacco smoking and MPMN in women, which 
deserves further study, as possible associations can 
give additional insights into which patients should re-
ceive PET/CT screening.
Of all 37 MPMN, eleven （29.7％） had a SUVmax ＜
3.0, with a mean tumor size of 14 mm （2–30 mm）. Of 
them, nine lesions were bigger than 10 mm：five were 
located in the stomach, two in the colon, one in the 
thyroid and another in the prostate. These sites have 
particularly increased physiological FDG uptake33）, hin-
dering the visualization of possible local malignant le-
sions. Moreover, some neoplasms are non-FDG-avid, 
such as low-grade tumors, mucinous and neuroendo-
crine tumors, renal cell carcinoma, and certain types of 
lymphoma34）. Therefore, if a tumor is suspected by the 
morphological component of PET/CT examination, fur-
ther specific screening test should be considered. In 
addition, dual-time FDG PET/CT imaging, meaning 
an early and delayed phase scan, may give extra de-
tails about the local metabolism allowing a better ap-
proach to suspicious FDG accumulations35）.
In this study, MPMN of the gastrointestinal tract 
women with a total of three thyroid, two breast, and 
two colon primary cancer lesions. Among the two men 
with BMI ≥  25, a total of four colorectal cancer lesions 
were diagnosed. On the contrary, of the six patients 
with underweight, a total of eight colon, three gastric, 
and a renal primary cancer lesions were found.
Table 2 describes the thirty-two patients and the 
characteristics of their thirty-seven lesions. Of the 32 
patients, 27 had double and 5 triple cancers. From a 
total of 37 MPMN, 17 colorectal lesions （45.9％） were 
the most common frequent, followed by stomach （9；
24.3％）, prostate （3；8.1％）, thyroid （3；8.1％）, breast 
（2；5.4％）, biliary duct （1；2.7％）, kidney （1；2.7％）, 
and lung （1；2.7％）. For the index cancer, SUVmax 
ranged between 1.5 and 45；and for the synchronous 
cancers, the SUV max ranged between 2 and 40. With-
in the MPMN found, 32 .4％ corresponded to stage 0 , 
78.4％ were at stages 0−I, and 91.9％ at stages 0, I, II. 
Moreover, 86.5％ were curatively resected.
??????????
Currently, there is an increasing need to find the op-
timal screening modalities and strategies to reduce 
mortality from second malignancies 10）； we believe 
that FDG PET/CT may play an important role as a 
reliable alternative for MPMN screening. In our study, 
FDG PET/CT was effective in finding 37 incidental 
primary lesions with a sensitivity of 76.5％ and a PPV 
of 70.3％ . Of them, 91.9％ were in early stage （0−II） 
and 86 .5％ were curatively resected. Other studies 
also agreed about the important role of preoperative 
staging with FDG PET/CT for MPMN evaluation and 
treatment11〜14）. In these studies, sensitivity and PPV 
rates were between 88％ −100％ and 59％ −93.7％, 
respectively. As in our study, most synchronous can-
cers were detected at an early stage with successful 
resection rates.
In 1 9 9 1 , the National Cancer Center Hospital 
（Tsukiji, Tokyo, Japan） reported a MPMN prevalence 
of 4 .0％ and noted an increase from 3％ in 196215）. 
With PET/CT, we found a prevalence of 4.1％ （32 of 
778 patients）, which contrasted with a compendious 
literature review about MPMN prevalence diagnosed 
by PET/CT （Table 3-1）11,16,17）, as well with the detec-
tion rate of primary cancer in healthy asymptomatic 
individuals during cancer screening with whole-body 
??（1） （2011） 13
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CRC was the most common within the 5 triple can-
cer patients. Whole-body PET/CT for tumor staging 
has increased the detection rate of unexpected syn-
chronous cancers. Although odds of having more than 
two synchronous primary neoplasms are small, PET/
CT may increase the prevalence38）.
Regarding the SUVmax for colorectal MPMN in this 
study, the mean SUVmax＝6.7±3.9 was comparable to 
those MPMN found by PET/CT colonography39）. The 
superimposition of the precise structural findings pro-
vided by CT to a hypermetabolic focus seen at PET 
were the most frequent （73.0％；seventeen colorectal 
and ten gastric of 37 cancers）. Of the 17 synchronous 
colorectal cancer （CRC）, 16 （94％） were at stage 0−I, 
which were successfully treated. These clinical charac-
teristics and pathological findings were similar to the 
colorectal synchronous lesions described in a prospec-
tive study36）. A predisposition for multiple primary col-
orectal carcinomas in patients with longstanding ulcer-
ative colitis （18％） and familial adenomatous polyposis 
（21％） is well known37）, however in our cases there 
was no familial genetic component.
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???????-?　Literature review for prevalence of MPMN detected by PET/CT.
Country Author
Total no. of patients 
with cancer
No. of patients 
with MPMN
％ Most frequent MPMN
Japan Suzuki（2008）a 43 1 2.3％ ESO
Japan Takekawa（2007）b 964 11 1.1％ BIL, CRC, HEP, LUN, PRO, STO, THY
Korea Choi（2005）c 547 26 4.8％ LUN, STO
Information from abstracts found in Pubmed under MeSH keywords：［“Positron-Emission Tomography” AND “Neoplasms, 
Multiple Primary”］. Cited 2010 Oct.
Abbreviation. MPMN：Multiple primary malignant neoplasm；UGI：upper gastrointestinal
［Site］ BIL：Biliary；CRC：Colorectum；ESO：Esophagus；HEP：Liver；LUN：Lung；PRO：Prostate；STO：Stomach；
THY：Thyroid
a. Aim to analyze the sensitivity of FDG-PET and FDG-PET/CT to detect upper gastrointestinal MPMN.
b. Report of MPMN found by PET/CT
c. Patients underwent PET/CT staging or restaging due to suspicion of primary cancer of UGI tract.
???????-?　Literature review for prevalence of primary tumors detected by PET/CT screening.
Country Author
Total no. of asyntomatic 
individuals
No. of individuals 
with cancer
％ Most frequent site
Japan Ide（2006）a 9,357 296 3.2％ CRC, LUN
Japan Nishizawa（2009）a 1,197 18 1.5％ THY
Korea Lee（2009）a 1,336 16 1.2％ THY
Japan Terauchi（2008）a 2911 28 1.0％ CRC
Japan Minamimoto（2007）a 50,558 395 0.8％ CRC, THY
Japan Kaida（2008）a 660 5 0.8％ BRE
Japan Kojima（2007）b 4881 36 0.7％ THY
Japan Ghotbi（2007）c Not stated Not stated 0.5％ Not stated
Japan Shoda（2007）d 2861 2 0.1％ STO
Information from abstracts found in Pubmed under MeSH keywords：［“Positron-Emission Tomography” and screening］. 
Cited 2010 Oct.
Abbreviation. ［Site］ BRE：Breast；CRC：Colorectum；LUN：Lung；STO：Stomach；THY：Thyroid
a. Cancer screening with whole-body PET/CT for healthy asymptomatic individuals.
b. Historical cohort study to evaluate the diagnostic performance of cancer screening using whole-body FDG-PET.
c. Cancer screening with whole-body PET/CT for healthy asymptomatic Japanese.
d. FDG-PET screening for upper gastrointestinal cancers compared with endoscopic diagnosis as the gold standard.
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